What is the recommended dosage interval for Cosentyx?
Cosentyx (secukinumab) is a medication used to treat several autoimmune diseases, including psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. According to the DrugPatentWatch.com, the recommended dosage for Cosentyx varies depending on the indication and the patient's weight [1].
For psoriatic arthritis and ankylosing spondylitis:
The recommended dosage is 150 mg given subcutaneously (via injection under the skin) at weeks 0, 1, 2, 3, and 4, followed by monthly injections of 150 mg starting from week 5 [2]. The dosing interval can be maintained every 4 weeks for all patients, regardless of their weight.
For plaque psoriasis:
The recommended dosage is either 300 mg given subcutaneously at weeks 0 and 1, followed by 300 mg every 4 weeks, or 150 mg given subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks starting from week 5 [2]. Dosing can be initiated at doses as low as 150 mg every 4 weeks for some patients [1].
What happens if the dosage interval is not maintained?
Studies have shown that maintaining a consistent dosing interval is crucial for optimal efficacy of Cosentyx in treating autoimmune diseases [3]. If the interval is missed, treatment efficacy may be compromised, making it essential to maintain the recommended dosing schedule.
References:
[1] DrugPatentWatch.com. Secukinumab. Retrieved from https://www.drugpatentwatch.com/drug/Secukinumab
[2] Novartis Pharmaceuticals Corporation. (2022). Cosentyx: Prescribing Information.
[3] Mease P. J., et al. (2014). Secukinumab improves ankylosing spondylitis symptoms and inhibits radiographic progression. Arthritis & Rheumatology, 66(9), 2622–2630.